Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2013

View Archived Issues

HDL mimetic peptide exerts cardioprotective activity and reduces atherosclerosis

Pneumonia case accrual completed for CAPiTA study of Prevenar 13

Seattle Genetics patents new monoclonal antibodies

New IL-1 beta antibodies disclosed by researchers in Singapore

New NIK inhibitors patented by Roche and Genentech

Favorable phase I trial results reported for novel anti-PSCK9 monoclonal antibody

BioTime cleared to begin human studies with Renevia

South African and Swiss teams claim new agents for malaria

U.S. and Hong Kong researchers disclose novel polypeptides for muscle disorders

Redbiotec and TeselaGen to collaborate on Herpes virus vaccine library

Sinupret dry extract demonstrates antiviral and anti-inflammatory activity

Astellas and MSD sign copromotion agreement for ipragliflozin in Japan

Heidelberg Pharma and Roche sign license agreement for antibody-targeted amanitin conjugates

U.K.'s NICE recommends NHS reimbursement for Jetrea

Benefit seen with ATX-MS-1467 in phase I multiple sclerosis trial

Susceptibility loci for hypertension identified in Japanese subjects

Polymorphism on chromosome 9p21 linked to prognosis after myocardial infarction

University of Warwick researcher wins drug discovery award from Domainex

Swissmedic opposes approval of Vitaros

Akorn to acquire Hi-Tech Pharmacal

World Health Organization prequalifies Menomune meningococcal vaccine

InVivo Therapeutics outlines development plan for spinal cord injury program

Initiation of phase I trial of PF-06263507 triggers milestone payment

Presidio Pharmaceuticals begins phase I hepatitis C study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...